2. Academic Validation
  3. The Selective WEE1 Inhibitor Azenosertib Shows Synergistic Antitumor Activity with KRASG12C Inhibitors in Preclinical Models

The Selective WEE1 Inhibitor Azenosertib Shows Synergistic Antitumor Activity with KRASG12C Inhibitors in Preclinical Models

  • Cancer Res Commun. 2025 Feb 1;5(2):240-252. doi: 10.1158/2767-9764.CRC-24-0411.
Nathan M Jameson 1,  Daehwan Kim 1,  Catherine Lee 1,  Blake Skrable 1,  Alexandra Shea 1,  Xiao Guo 1,  Hooman Izadi 1,  Mona Abed 1,  Olivier Harismendy 1,  Jianhui Ma 1,  Doris S Kim 1,  Mark R Lackner 1
Affiliations

Affiliation

  • 1 Zentalis Pharmaceuticals, Inc., San Diego, California.
PMID: 39807828 DOI: 10.1158/2767-9764.CRC-24-0411
Abstract

Resistance to KRASG12C inhibitors is a growing clinical concern. The synergistic interaction observed between azenosertib and multiple KRASG12C inhibitors could result in deeper and more durable responses.

Figures
Products